◆英語タイトル:Prescient Therapeutics Ltd (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013250
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the AKT pathway, that is used in the development of various cancers, including ovarian and breast cancer as well as hematologic cancers such as acute myeloid leukemia; PTX-100, a drug that is used to kill cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). It develops immunotherapeutic products based on its Co-X-Gene technology platform. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.
Prescient Therapeutics Ltd (PTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 10
Equity Offering 12
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 12
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 13
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 14
Virax Announces Private Placement Of Shares For US$2.7 Million 15
Virax Completes Private Placement Of Units 16
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 17
Virax Completes Rights Issue Of Common Stock For US$0.53 Million 18
Acquisition 19
Virax Acquires Pathway Oncology 19
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 20
Prescient Therapeutics Ltd – Key Competitors 21
Prescient Therapeutics Ltd – Key Employees 22
Prescient Therapeutics Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Jan 15, 2016: Steven Yatomi – Clarke Appointed CEO: Prescient Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List of Tables
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prescient Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 10
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 12
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 13
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 14
Virax Announces Private Placement Of Shares For US$2.7 Million 15
Virax Completes Private Placement Of Units 16
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 17
Virax Completes Rights Issue Of Common Stock For US$0.53 Million 18
Virax Acquires Pathway Oncology 19
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 20
Prescient Therapeutics Ltd, Key Competitors 21
Prescient Therapeutics Ltd, Key Employees 22
Prescient Therapeutics Ltd, Subsidiaries 23